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Abstract
Recent evidence suggests that transient hyperglycemia in extremely low birth weight infants is strongly associated with the
occurrence of retinopathy of prematurity (ROP). We propose a new model of Neonatal Hyperglycemia-induced Retinopathy
(NHIR) that mimics many aspects of retinopathy of prematurity. Hyperglycemia was induced in newborn rat pups by
injection of streptozocine (STZ) at post natal day one (P1). At various time points, animals were assessed for vascular
abnormalities, neuronal cell death and accumulation and activation of microglial cells. We here report that streptozotocin
induced a rapid and sustained increase of glycemia from P2/3 to P6 without affecting rat pups gain weight or necessitating
insulin treatment. Retinal vascular area was significantly reduced in P6 hyperglycemic animals compared to control animals.
Hyperglycemia was associated with (i) CCL2 chemokine induction at P6, (ii) a significant recruitment of inflammatory
macrophages and an increase in total number of Iba+ macrophages/microglia cells in the inner nuclear layer (INL), and (iii)
excessive apoptosis in the INL. NHIR thereby reproduces several aspects of ischemic retinopathies, including ROP and
diabetic retinopathies, and might be a useful model to decipher hyperglycemia-induced cellular and molecular mechanisms
in the small rodent.
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Background
Retinopathy of prematurity (ROP), is one of the major causes of
visual impairment in children. It is characterized by an initial
retardation of the progression of vascular growth toward the
retinal periphery which predisposes to abnormal compensatory
neovascularisation [1]. Low birth weight, low gestational age and
supplemental oxygen therapy are the major risk factors for the
development of ROP. In the very low birth weight infant,
hyperglycemia occurs frequently, especially in the first weeks after
birth [2,3,4,5]. Elevated blood glucose concentration has been
recognized as an additional and independent risk factor for ROP
irrespective of the threshold used to define hyperglycemia
(between 144 and 180 mg/dl) [6,7,8,9,10,11]. Each 10 mg/dL
increase of mean serum glucose has been shown to increase the
risk of ROP 2.7 fold [9] and each additional day of hyperglycemia
increase the risk to develop the disease by 7% [11].
In diabetic adults, adverse effects of poor glycemic control and
hyperglycemic state on retinal vasculature and function are well-
known [12]. The features and mechanisms of diabetic retinopathy
(DR) have been extensively studied in spontaneously diabetic and
streptozotocin-induced retinopathy in adult rodents. The effects of
hyperglycemia on the developing retina remain unknown.
The objectives of this work were to characterize the effect of a
moderate, clinically relevant, hyperglycemic phase on vascular
development. Our results show that neonatal hyperglycemia very
reproducibly induces severe inflammation, inhibition of physio-
logical angiogenesis and neuronal degeneration in a very short
period of time. Neonatal hyperglycemia retinopathy (NHIR)
might be useful to help decipher hyperglycemia-induced cellular
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and molecular mechanisms in the retina that lead to diseases such
as ROP and DR.
Methods
Ethics
All experimental protocols and procedures were approved by
the local animal care ethics committee ‘‘Comite´ d’e´thique en
expe´rimentation animale Charles Darwin’’ (Nu p3/2008/54) and
met the INSERM guidelines.
Animals
One day-old Lewis rat pups were used for the experiments.
Pregnant animals were purchased from Janvier - Le Genest- St-
Isle, France. Animals were housed at local animal facilities under
12/12 hours light/dark cycles and fed ad libitum. The number of
pups was culled to 8–10 per litter at P1 by random selection.
Model of Neonatal Hyperglycemia
The model of neonatal hyperglycemia was adapted from
previously published studies [13,14,15] using streptozotocin
(STZ) (Sigma-Aldrich Chemical Co, Saint-Quentin Fallavier,
France). For each experiment, aliquots of STZ were pre-weighed,
wrapped in aluminium foil and stored in 220uC. STZ was
dissolved in the citrate buffer (20 mmol/l) immediately before the
injection to a final concentration of 10 mg/ml. 50 mg/kg (5 ml/g),
was administered via intraperitoneal injections in the lower left
quadrant of the abdomen, using a 29G needle (total volume
injected = 25 to 30 ml depending on individual animal’s weight).
Control (CTL) animals received an equal volume of citrate buffer.
The pups were returned to their dams after the injection. Before,
and daily after STZ injection, animals were weighted and tail
blood was collected for glucose determination using a standard
patient glucometer (Accu-ChekH Performa, Roche Diagnostics,
Meylan, France). Insulin blood levels were determined by ELISA
using Mercodia Rat Insulin Assay (Mercodia SAS, Paris, France)
according to manufacturer recommendations. Some rat pups were
injected intravitreally with 1 ml of 1 mg/ml STZ at P3 to assess its
toxicity on the developping retina.
Immunohistochemistry
Pups were sacrificed serially by decapitation at P3, P4, P5, P6
and P7 (2 to 6 days after the STZ injection). Some rat pups were
also assessed at P21, when the maturation of the retina is complete
and the hyperglycemia has resolved. After sacrifice, eyes were
removed and retinas were dissected and fixed in 4% paraformal-
dehyde for 20 minutes at room temperature prior to flatmounting
or OCT (Tissue TekH) embedding. Intraretinal vascularization
and microglial cell density were assessed on whole retinal
flatmounts. Retinal capillaries were labeled according to previ-
ously described standard immunohistochemical procedures [16],
using goat polyclonal anti-collagen IV antibody (1/400, AbD
Serotec, Cergy Pontoise, France) and Isolectin B4-FITC (Ib4)
(Sigma Aldrich Chemical Co, Saint-Quentin en Yvelines, France).
Pericytes were stained using NG2 antibody (1/200, Millipore,
Saint-Quentin Fallavier, France) and microglia was labeled using
rabbit polyclonal anti-Iba1 (1/400, Wako Pure Chemical Indus-
tries, Neuss, Germany). The corresponding Alexa–conjugated
secondary antibodies (Invitrogen, Cergy Pontoise, France) were
used to reveal the primary antibodies.
OCT-embedded retinas were cryosectioned and sections
through the optic nerve were used for immunolabeling. Frozen
sections were stained according to previously described standard
procedures. In addition to the antibodies used on retinal
flatmounts, the following primary antibodies were used to study
retinal cells type on cryosections: anti-Ap2a antibody (3B5, for
amacrine and horizontal cells) was purchased to Developmental
Studies Hybridoma Bank (DHSB, Iowa city, Iowa); mouse anti-
glutamine synthetase antibody (MAB302, for Muller cells) was
obtained from Millipore (Saint-Quentin Fallavier, France), and
rabbit anti-protein kinase Ca antibody (PKCa) (Sc-208, for
bipolar cells) from Santa Cruz (Heidelberg, Germany). Anti-
calretinin antibody (AB5320, Millipore, Saint-Quentin en Yve-
lines, France) was used to label horizontal cells, and anti-Rho4D2
(kind gift of Dr D. Hicks) to label rods. GFAP antibody (Sigma-
Aldrich, Saint Quentin Fallavier, France) was used to label
astrocytes. The corresponding Alexa–conjugated secondary anti-
bodies (Invitrogen, Cergy Pontoise, France) were used to reveal the
primary antibodies. The FITC conjugated-peanut agglutinin
(PNA) was used to label cone photoreceptor (Sigma Aldrich
Chemical Co, Saint-Quentin en Yvelines, France). Sections were
counterstained with DAPI.
Assessment of retinal vascularization and quantification
of microglial cell density
Sections and flatmount images were captured with a DM5500
microscope (Leica, Nanterre, France) equipped with an ORCA
ER Hamamatsu camera and analyzed by MetaMorph software
(Molecular Devices, Saint-Gregoire, France). For each retina, tube
length and branching of capillaries, and vascular density were
measured on a minimum of 6 representative images (1 to 2 mm2)
using the ‘‘angiogenesis tube formation’’ MetaMorph add-in
(Molecular Devices, Saint-Gregoire, France). Parameters were set
to select vessels between 3 and 40 mm. Vascularized areas were
measured and expressed as percent of total retinal area [16]. Iba1-
positive cell body size, cell perimeter (length around the periphery
of each cell), process length (average distance from the cell body to
its detected extremes) were measured on flatmounts using
MetaMorph software (Molecular Devices, Saint-Gregoire,
France). Cell roundness was calculated as described by Kozlowski
et al [17].
Histology/assessment of neurons layers
Pups exposed to hyperglycemia and their controls were
sacrificed at P14 (when neuronal development and differentiation
are at their end in rodent species), and retinas were immediately
dissected and fixed in 0.5% glutaraldehyde, 4% paraformaldehyde
PBS for 2 hours, dehydrated, and mounted in HistoResin.
Sagittal, oriented sections (5 mm), crossing the inferior pole, optic
nerve, and superior pole were cut (ultramicrotome Reichert
Ultracut E, Leica, Nanterre, France), and stained with toluidin
blue. Sections were photographed with a light microscope (Leica,
Nanterre, France) and numbers of rows of the outer nuclear layer
as well as number of the nuclei of the inner nuclear and ganglion
cell layers were quantified at different distances from the optic
nerve to the periphery.
Reverse Transcription and Real-Time Polymerase Chain
Reaction
Pups exposed to hyperglycemia and their normoglycemic
controls were sacrificed at P6. Retinas were dissected and total
RNA was extracted using the Nucleospin RNAII Kit (Macherey-
Nagel, Hoerdt, France). Retrotranscription was performed using
superscriptII (Invitrogen, Cergy-Pointoise, France). Real-time
PCR was performed using 7300 Real-Time PCR System (Applied
Biosystems, Cergy-Pointoise, France) in a 20 ml final volume with
Power SYBR Green PCR Master Mix (Applied Biosystems,
Neonatal Hyperglycemia-Induced Retinopathy
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Cergy-Pointoise, France) and 0.25 mM primers. All samples were
run in triplicate. Primers used for real-time PCR analysis are
available upon request.
Statistical analysis
All data are reported as mean +/2 SEM unless otherwise
indicated. Data were analyzed by unpaired t-test or one- and two-
way ANOVA with Bonferroni post-tests, according to the number
of groups compared (GraphPad Software Inc., San Diego, USA).
p,0.05 was considered as statistically significant.
Results
STZ leads to transient hyperglycemia without growth
retardation in newborn rats
Hyperglycemia was induced by low STZ dose intraperitoneal
injection at ages during which both the neural retina and the
retinal vasculature are immature [18,19]. Pilot studies determined
50 mg/kg as the lowest dose of STZ that induced sustained
elevated glycemia without inducing life-threatening hyperglyce-
mia. All animals were injected at postnatal day 1 (P1) with STZ
(50 mg/kg) in citrate buffer (STZ group) or with the control
vehicle (citrate buffer, CTL group). Administration of STZ
resulted in a moderate increase of blood glucose concentration
reaching 155 mg/dl (8.6 mmol/l) within 24 h following injection.
Glycemia was significantly increased from P3 to P6, averaging
214 to 241 mg/dl (11.9–13.4 mmol/l) (Fig. 1A). At P6, values in
STZ-injected pups ranged from 104 to 496 mg/dl with a mean
value of 219.4+/217.59 SEM (n= 51). A few animals experienced
glycemia above 400 mg/dl between P3 and P6 (n= 3). The values
in STZ-injected pups were not significantly different from controls
beyond P7 (average CTL, 121.9 mg/dl, n = 14; average STZ,
136.8 mg/dl, n = 14, two-way Anova followed by Bonferroni post-
test) (Fig. 1A). To monitor the efficiency of STZ-induced
pancreatic Langerhans cell death we determined insulin blood
levels in control and STZ animals. At P6, after 3 consecutive days
of hyperglycemia, STZ injection resulted in a significant decrease
in circulating insulin in STZ animals when compared to control
group (0.32+/20.07; n = 10 vs 0.17+/20.01; n = 15, unpaired t-
test, p = 0.02) (Fig. 1B). As decreased levels of insulin may affect
survival of newborn animals we determined animal survival.
Survival was minimally impacted by STZ and hyperglycemia and
no significant difference was observed in death rate between the
control and the STZ group following injection (Fig. 1C). Weight
gain was not affected in hyperglycemic animals when compared to
normoglycemic control animals (Fig. 1D).
STZ toxicity is dependent on glucose transporter GLUT2,
through which it enters the cell. GLUT2 is strongly expressed on
Langerhans cells [20]. It is not expressed on adult retinal neurons
[21] and STZ has no direct toxicity on the mature retina
[22,23,24]. To evaluate direct STZ susceptibility of the developing
retina we assayed GLUT2 expression by qPCR during retinal
development and compared it to adult pancreas and retina. P6
and adult rat retina GLUT2 expression was similar and 22.6 fold
Figure 1. STZ leads to transient hyperglycemia without growth retardation in neonates. P1 rat pups were injected with low doses of
streptozotocin in citrate buffer (STZ) or with the control vehicle (citrate buffer, CTL). A. Measurements of glycemia from P1 to P21 in both groups. The
STZ group displayed a moderate increase in glycemia from P3 to P6, averaging 214 to 241 mg/dl (11.9–13.4 mmol/l). B. Insulin concentration in
serum at P6 in control (white) and STZ treated (black) animals. The STZ group demonstrated a decreased level of insulin. C. Survival curve in STZ- and
CTL-groups. Mortality was similar in both groups. D. Weight from P1 to P21 in STZ- and CTL-groups. Weight gain was not affected in STZ-injected
animals when compared to control animals. Data in A and D were analyzed by a two-way ANOVA followed by a Bonferroni post test. Data in B were
analyzed by an unpaired t-test. Data in C were analyzed by a Log-rank test. * P,0.05.
doi:10.1371/journal.pone.0079545.g001
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lower than in adult rat pancreas (Fig. 2A). We next assayed toxicity
of STZ to retinal vasculature by injecting STZ directly into the
vitreous (IVT) of newborn rats at P1. IVT injection neither
affected weight gain nor glycemia (data not shown). Retinal
vasculature was stained at P6 using an anti-collagen IV antibody
in CTL and STZ animals (Fig. 2B). A software analysis tool was
used (Fig. 2C) to determine, the vascularized retinal area (Fig. 2D),
the mean tube length of the vessels (Fig. 2E), the number of branch
point per mm2 (Fig. 2F) and the total tube length per mm2
(Fig. 2G). These parameters were not affected by STZ IVT
injection, demonstrating an absence of vasculature toxicity of STZ
in the newborn retina (p.0.05, unpaired t-test).
Retinal angiogenesis is inhibited in hyperglycemic
animals
Prolonged periods of hyperglycemia induce pericyte and
endothelial cell death resulting in microvascular degeneration in
the adult [25]. To evaluate the effect of moderate hyperglycemia
on retinal vascular development we visualized the basal membrane
of the retinal vasculature using an anti-collagen IV antibody at
different time points of the hyperglycemic phase (Fig. 3A and B
illustrate P6 vasculature in control and hyperglycemic animals
respectively) and quantified retinal vascularization (Fig. 3C). While
the vascularized retinal area was similar in control and STZ-
treated animals at P3 and P4, a significant decrease in vascular
area was found at P5, after 2 days of hyperglycemia (9.2%+/21.8
(n = 6)) (Fig. 3C). At P6, inhibition of vascularization reached
15.6%+/21.8 (n = 16) (Fig. 3A–C). Tube length, branch point
density and total tube length per mm2 was determined at P6 in
control and STZ groups to evaluate vessel density. No significant
differences were found between groups (Fig. 3D). Similar results
were obtained with the Ib4 lectin that stains viable endothelial cells
(data not shown). The total retinal size in control and STZ injected
animals at P6 was not significantly different (average CTL
30.0 mm2, average STZ 28.4 mm2, n= 30, unpaired t-test,
p = 0.53). At P21, vessel density of the superficial plexus was
evaluated. No differences were observed between control and STZ
retinas (Fig. 3E–F).
Astrocytes enter the developing retina from the brain along the
developing optic nerve during the first 10 postnatal days of rat
retinal development [26]. GFAP positive astrocytes were correctly
located in the GCL and no sign of reactive gliosis was detected in
Mu¨ller cells in the hyperglycemic animals (Fig. 4A, C). When
observed on retinal flatmount at P6, astrocyte processes bundle in
contact with the vessels in the vascularized area giving rise to a
more vascular pattern (Fig. 4B). In the hyperglycemic animals,
astrocyte cell processes in the vascularized area stayed evenly
distributed at the surface of the retina regardless of the vasculature
pattern resembling their appearance in the non-vascularized retina
at P6 (Fig. 4D). Vessel coverage by pericytes was evaluated using
Figure 2. Intravitreal injection of STZ does not modify retinal vasculature. A. Glucose transporter GLUT-2 expression (RT-PCR) in newborn
and adult retinas, as compared to adult pancreas. GLUT-2 expression was similar in P6 and adult retina but 22.6 fold lower than in adult pancreas. B–
F. P1 rat pups were injected intravitreously with streptozotocin (STZ) or with the citrate buffer vehicle (CTL). B. Retinal flatmounts of P6 CTL or STZ
animals were stained using anti-collagen IV antibody. C Representative automated analysis of vascular density using Metamorph software. Branch
points are represented by green points and tubes by solid gray lines (lower panel). D–G. Vascular area, mean tube length, branch point density and
total tube length density were determined at P6 in hyperglycemic (black bars) or control (white bars) animals. Values in histograms D–G are mean 6
SEM of retinas from 8 animals per group from at least 2 different experiments. Data were analyzed by unpaired t-tests. No significant differences were
found in these parameters.
doi:10.1371/journal.pone.0079545.g002
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pericyte marker NG2 (Fig. 4E–H). Similar to control animals,
NG2 staining in STZ-injected animals was found throughout the
retinal vasculature up to the vascular front at P6 (data not shown).
Higher magnification analysis of the vasculature did not reveal any
signs of pericyte coverage loss (Fig. 4E–F) nor pericyte retractions
(Fig. 4E–F insets) in animals with hyperglycemia around 214 to
241 mg/dl. Interestingly signs of pericyte coverage loss, capillary
loss (Fig. 4G, g, g9, arrows), and pericyte retraction (Fig. 4H) were
found in 3 animals that developed glycemia above 400 mg/dl.
Neuronal and Muller cell genesis in hyperglycemic
animals
Retinal neurons and Mu¨ller glial cells develop from a common
pool of progenitors from E14 to P10 [19]. To evaluate if
hyperglycemia blocks the generation of a particular retinal neuron
or macroglia, we analyzed the expression of retinal specific
markers of the inner nuclear layer (INL) and the outer nuclear
layer (ONL) by immunohistochemistry in the mid peripheral
retina at P6. Positive cells for PKCa (on bipolar cells), Ap2a
(amacrine cells) and calretinin (horizontal cells) (Fig. 5A) were
generated and correctly located in the INL of both group. PNA
positive (cones) and Rho4D2 (rods) (Fig. 5B) photoreceptors were
present in CTL and STZ P6 animals. Mu¨ller cells are the last cell
type to be differentiated from retinal progenitors. There was no
obvious difference in glutamine synthetase staining (Mu¨ller cells) of
both the STZ and control, suggesting that Mu¨ller cells are
generated in both groups similarly (Fig. 5C). Hyperglycemia did
not block the generation of a specific cell type in particular.
Hyperglycemia induces apoptosis and retinal
degeneration
ROP leads to long-term impairment of retinal function [27] and
diabetes induces neuronal apoptosis and degeneration in patients
and in adult diabetic animal models [28,29,30]. To examine
apoptosis in hyperglycemia induced retinopathy we performed
TUNEL staining (red staining) on P6-old control (Fig. 6A–B) and
hyperglycemic animals (Fig. 6C–D). In normoglycemic animals
some TUNEL positive nuclei can be observed in the periphery of
the GCL, while no or little apoptosis is observed in the INL and
ONL. In contrast, hyperglycemic rat pups presented numerous
TUNEL positive nuclei in the INL and ONL (fig. 6C–D). Higher
magnification of TUNEL positive nuclei showed additional
morphological signs of apoptosis such as fragmentation (Fig. 6E).
Co-immunostaining with cell-specific markers did not allow the
identification of a particularly affected cell type in the INL (data
not shown). To evaluate if the observed increased apoptosis leads
to permanent alteration of the retinal morphology, we compared
toluidin blue-stained retinal sections of control (Fig. 6F) and
hyperglycemic animals (Fig. 6G) at P14, when retinal stratification
is physiologically mature. Nuclei of the GCL (Fig. 6H), the INL
(Fig. 6I) and ONL (Fig. 6J) were quantified in hyperglycemic
(STZ) and normoglycemic animals (CTL). While we did not
observe differences in the GCL (measured as the number of cells
per 100 mm), the numbers of nuclei of the INL (measured as the
number of cells per 100 mm) and ONL (quantified as the number
of rows) were significantly diminished in the STZ group. Nuclear
layers in the central retina were less affected. In some hypergly-
cemic animals, more severe alterations of the outer nuclear layer
were also seen, such as aberrant cells protruding into the subretinal
space (Fig. 6K) and large folds of the ONL (Fig. 6L).
Hyperglycemia leads to retinal inflammation
Microglial cells (MC)/macrophages (MP) have been shown to
be activated in experimental and human diabetic retinopathy
[31,32,33,34,35]. To evaluate MC/MP activation in neonatal
hyperglycemia we labeled retinal flatmounts of control (Fig. 7A–C)
and hyperglycemic pups (Fig. 7D–F) with the specific microglial
Figure 3. Retinal angiogenesis is inhibited in hyperglycemic
animals. P1 rat pups were injected with low doses of streptozotocin
(STZ) or with the citrate buffer vehicle (CTL). A–B. Retinal flatmounts of
P6 CTL (A) or STZ (B) animals were stained using anti-collagen IV
antibody. Vascularized area circumferences are highlighted in red. C.
Vascular area measurement in hyperglycemic (black bars) or control
(white bars) animals. Values in histograms are mean 6 SEM of vessel
area of retinas from 4–8 animals per group from 3 different
experiments. * P,0.05 compared to CTL, two-way ANOVA, Bonferroni
post-test. D. Mean tube length, branch point density and total tube
length density were determined at P6 in hyperglycemic (black bars) or
control (white bars) animals. Values in histograms are mean 6 SEM of
retinas from 4–8 animals per group from 3 different experiments. E.
Higher magnification of P21 retinal flatmounts of CTL and STZ animals
stained with collagen IV antibody. F. Mean tube length, branch point
density and total tube length density were determined at P21 in
hyperglycemic (black bars) or control (white bars) animals. Values in
histograms are mean6 SEM of retinas from 4 animals per group from 2
different experiments. Scale bar 1 mm in A–B; 200 mm in E–F. No
statistical differences in vessel parameters were found in D and F
between STZ and control groups using unpaired t-tests.
doi:10.1371/journal.pone.0079545.g003
Neonatal Hyperglycemia-Induced Retinopathy
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e79545
cell/macrophage marker Iba1. Quantification of Iba1-positive
MC/MP density at the beginning (P3), during (P6) and after
hyperglycemia (P21) revealed a significant increase of retinal Iba1-
positive cells by 80% in STZ injected pups at P6 (Fig. 7G and
compare Fig. 7E and 7B) that renormalized at P21 after 14 days of
renormalized glycemia (Fig. 7G and compare Fig. 7F and 7C).
Iba1-stained retinal sections and flatmounts at P6 of control
(Fig. 7H and I) and hyperglycemic pups (Fig. 7J and K) showed
that retinal MC/MPs were physiologically mainly located in the
GCL and IPL at P6 (Fig. 7H). Hyperglycemic animals additionally
displayed many enlarged and rounded MC/MPs in the INL
(Fig. 7J and K). To quantify the morphological signs of activation
of the Iba1-positive cells, we analyzed the Iba1+ cells in the inner
retina of control (Fig. 7I) and hyperglycemic rat pups (Fig. 7K).
Figure 4. Astrocytes and pericytes phenotype in NHIR. P1 rat pups were injected with low doses of streptozotocin (STZ) or with the citrate
buffer vehicle (CTL). A–D. Retinal flatmounts and sections of P6 CTL (A–B) and STZ (C–D) were co-stained using anti-collagen IV antibody and anti-
GFAP antibody. E–F Retinal flatmounts of P6 CTL (E) and STZ (F) were co-stained using anti-collagen IV antibody and or anti-Ng2 antibody. G–H. STZ
animals with hyperglycemia .400 mg/DL were co-stained using anti-collagen IV antibody and anti-Ng2 antibody. Nuclei were counterstained with
DAPI in A and C. Scale bar 50 mm in A–G, g and g9; 5 mm in E and F insets and H.
doi:10.1371/journal.pone.0079545.g004
Figure 5. Neuronal and Muller cell genesis in hyperglycemic animals. A–C. Retinal sections of CTL and STZ-treated P6 rat pups were stained
with various antibodies specific to neurons of the INL (A), photoreceptors cells (B) and glial cells (C) of the retina. A: INL neuron generation was not
affected by hyperglycemia and similar patterns of staining (red) were observed in CTL and STZ animals for PKCa (bipolar cells), Ap2a (amacrine cells)
and calretinin (CALR, horizontal cells). B. Photoreceptor generation was not affected by hyperglycemia and similar patterns of staining (red) were
observed for peanut agglutinin (PNA, cones), Rho4D2 (R4D2, rods) in STZ P6 animals compared to CTL. C. Muller cells cell genesis was not affected by
hyperglycemia when compared to CTL. Nuclei were counterstained with DAPI. Scale bars 50 mm. GCL=ganglion cell layer; INL = inner nuclear layer;
ONL=outer nuclear layer.
doi:10.1371/journal.pone.0079545.g005
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Iba1+ cells in hyperglycemic animals show an increase in the cell
body size and cell roundness (Fig. 7L), a shortening of the cell
ramification, and a decrease of their cell perimeter length (Fig. 7L).
None of these parameters were affected by direct injection of STZ
in the vitreous at P1 demonstrating an absence of direct role of
STZ on Iba1+ cells activation (data not shown). Activated MC/
MPs express inflammatory cytokines such as CCL2, TNFa, and
IL-1b in experimental diabetes [32,36,37]. Real time RT-PCR
analysis of mRNA extracts of P6 retina revealed a significant
increase of Ccl2 (2.54+/20.45 vs 0.92+/20.21), Tnfa (2.47+/
20.47 vs 1.00+/20.27), and Il-1b (3.35+/20.68 vs 1.00+/20.60)
in the STZ-injected hyperglycemic group compared to controls
(n = 5, p,0.05, unpaired t-tests) (Fig. 7M). iNos was undetectable
in both groups (data not shown).
Discussion
Here we show that clinically relevant hyperglycemia during
retinal development significantly inhibits retinal angiogenesis,
induces neuronal cell death and leads to MC/MP infiltration
and inflammatory cytokine production. Neonatal Hyperglycemia-
induced retinopathy is an inexpensive, reproducible and quanti-
fiable model that mimics retinopathy of prematurity.
Our goal was to develop a model of clinically relevant neonatal
pathological hyperglycemia, with sustained levels of hyperglycemia
at the time when angiogenesis and neuronal development take
place in the retina [18,19]. In a study by Hays et al., 42% of
extremely low birth weight infants (birth weight ,1000 g) had
blood glucose concentrations consistently above 150 mg/dl
(8.25 mmol/l) in the first week of life; for 6% of them, blood
Figure 6. Hyperglycemia induces apoptosis and retinal degeneration. A–D. Retinal sections of STZ (C, D) and CTL (A, B) P6 animals were
stained with the TUNEL labeling kit (red) and counterstained with DAPI. TUNEL labeling revealed the presence of apoptotic and fragmented nuclei in
the INL of STZ retina (E). F–G. Representative histological toluidin-blue stained retinal sections in CTL (F) and STZ (G) P14 rat pups. H–I. Quantification
of the number of nuclei per 100 mm in the central part (C) and the periphery (P) of the ganglion cell layer (H) or the INL (I), in hyperglycemic (black
bar) and normoglycemic P14 animals (white bar). J. Quantification of the number of row of photoreceptor nuclei in the central part (C) and the
periphery (P) of the retina, in hyperglycemic (black bar) and normoglycemic P14 animals (white bars). Values are mean +/2 SEM of 9–10 retinas from
2 different experiments (H; I; J). * p,0.05; one-way ANOVA followed by Bonferroni post-tests. The number of nuclei in the INL and ONL was
significantly reduced in STZ animals compared to CTL; this effect was predominant at the periphery of the retina. K–L. Representative histological
toluidin-blue stained retinal sections of P14 STZ rat pups showing advanced structural disorganization with rosettes (K) and folds in the outer nuclear
layers (L). Scale bars: 100 mm in A and C; 50 mm in B and D; 5 mm in E; 20 mm in F, G, K and L. GCL =ganglion cell layer; INL = inner nuclear layer;
ONL=outer nuclear layer.
doi:10.1371/journal.pone.0079545.g006
Neonatal Hyperglycemia-Induced Retinopathy
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e79545
glucose concentrations were consistently above 250 mg/dl [4]. In
the NIRTURE study, 33% of the very low birth weight infants
(birth weight ,1500 g) enrolled in the control group had glucose
levels above .180 mg/dl (10 mmol/l) more than 10% of the time
[2]. Our model reproduced hyperglycemia within ranges of those
experienced by sick premature infants [2,3,4,5] (Fig. 1).
We induced a moderate diabetic state with low mortality and
little impact on body weight gain (Fig. 1), which is important since
poor weight gain has been shown to be a risk factor for ROP in
humans and in animal models [38]. Premature babies and type-1
diabetic patients are characterized by low insulin levels relative to
their hyperglycemic state [39]. We here show that STZ injection
Figure 7. Effect of neonatal hyperglycemia on macrophage/microglial cells (MP/MC) recruitment. A–F. Retinal flatmounts and sections
were stained with Iba-1 antibody. Representative flatmounts and sections of control (A, B) and STZ (D, E) P6 animals or P21 animals (C, F). G.
Quantification of Iba-1 positive cells at different time points in CTL (white bars) and STZ (black bars) animals. MC recruitment peaked at 5–6 days
postnatal. Values are mean +/2 SEM. *p,0.05 Two-way ANOVA, Bonferroni post-test. H–K. Retinal sections and flatmounts of CTL (H–I) and STZ
animals (J–K) were stained with Iba-1 antibody. MC/MP were located deeper in the retina of in hyperglycemic animals, reaching the inner nuclear
layer (J) and displayed a change in their morphology, with round, bloated bodies and short ramifications indicative of an activated state (K). L. Cell
body size, number of processes, length of the processes and perimeter length of Iba1 positive cells were determined for control (white bars) and
hyperglycemic (black bars) animal at P6. Values in histograms are mean 6 SEM of at least 50 cells selected in 3 different experiments. *p,0.05,
Unpaired t-tests.M. Real-time PCR of Ccl2, Tnfa and Il-1b in P6 rat pups retinas exposed to hyperglycemia (STZ, black bars; n = 5) compared to controls
(CTL, white bars, n = 5). *p,0.05, Unpaired t-tests compared to controls. Nuclei were counterstained with DAPI in H and J. Scale bars: 1 mm in A and
D; 50 mm in B–C, E–F and H–K. GCL =ganglion cell layer; INL = inner nuclear layer; ONL= outer nuclear layer.
doi:10.1371/journal.pone.0079545.g007
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in the neonate rat recapitulates hyperglycemia with low, but not
null, levels of insulin. Insulin has neuroprotective effects [40] and
the lack of insulin, as a neuro-trophic factor, encourages the loss of
retinal neurons observed in diabetes [41] and possibly in
hyperglycemic premature babies with ROP. We dosed the STZ
so that our animals do not require insulin injections for survival, to
avoid the potential neuro-trophic effects that would interfere with
the model.
STZ is a widely accepted tool for examining the mechanisms of
diabetic retinal injury and potential therapeutic interventions as
shown by its extensive use in adult animals [42]. We here show
that injection of STZ in the vitreous of newborn rats did not affect
angiogenesis nor trigger inflammation in the retina (Fig. 2 and
data not shown). Extrapancreatic effects of high doses of STZ have
been shown in the liver and the kidney [22,43]. It is possible that
similarly STZ injection affects neonate organs. The unique
50 mg/kg injection used in our protocol compared to multiple
50–150 mg/kg injections in adult models possibly mitigated
potential non-specific effects of STZ in pups. No edema or growth
retardation was observed in STZ-treated pups, indicating that
gross organ function was preserved and only the nenonates with
glycemia .400 mg/l and above, (n = 3) were moderately icteric.
Elevated blood glucose concentration in the neonatal period has
recently been recognized as an independent risk factor for
development of ROP in very low birth weight infants
[6,7,8,9,10,11]. Garg et al. showed that for each 10 mg/dl
increase of mean serum glucose, there was a 2.7-fold increase in
the risk of developing ROP [9]. Blanco et al. also found that
hyperglycemia .150 mg/dl was associated with a 4.6-fold
increase in the incidence of ROP [6]. In a population of extremely
low birth weight infants who did not receive insulin therapy,
Mohamed et al. showed that infants with ROP experienced a
greater mean number of days with hyperglycemia defined as
whole blood glucose.150 mg/dl (7 days vs. 2 days, p =,0.0001);
each day of hyperglycemia increased the risk of ROP by 7% [11].
We here show that 4 days of moderate hyperglycemia suffice to
significantly inhibit the progression of the vascular ridge, reflected
by a reduced vascularized retinal surface (Fig. 3) similar to ROP.
ROP leads to long-term impairment of retinal function [27] and
diabetes induces neuronal apoptosis and degeneration in patients
and in adult diabetic animal models [28,29,30]. Similarly, NHIR
resulted in a decreased thickness of the peripheral INL and ONL
at P14 when the retinal layering is mature (Fig. 6). We have
observed an un-physiological apoptosis in the peripheral INL and
in the ONL (Fig. 6). Our results favor a role of NHIR in
degenerating retinal neurons rather than blocking their generation
as all retinal cell types were present at P6 (Fig. 5). Further
experiments are required to analyze quantitatively retinal neurons
differentiation in NHIR. In one third of the eyes, the peripheral
retina showed advanced structural disorganization with folds and
rosettes in the outer nuclear layers, which we interpreted as
evidence of developmental dysplasia. In human ROP, as well as in
animal models of OIR, impairment of the function of the
photoreceptors and the post-receptor retina has been well-
established using full-field electroretinographic and psychophysical
studies [44]. Histopathologic features described in oxygen-exposed
retinas include attenuation of all inner layers of the retina [45,46],
thinning and disorganized aspect of the outer plexifom layer [47],
and loss of the regular stacking of the nuclei of the ONL and
appearance of vacuolization [48].
Recent data suggest that inflammatory processes may partici-
pate in the pathophysiology of ROP, since inflammatory cytokines
have been found to be increased in ROP eyes [49,50]. We here
show that hyperglycemia in the newborn rat led to a strong MP/
MC accumulation and activation (Fig. 7). Iba1-positive cell counts
showed a 80.9% increase at the peak of hyperglycemia at postnatal
day 6. Furthermore, these cells also displayed an activated
morphology, with shortening of their cellular processes and
enlarged and round body. Finally, Ccl2, Tnfa and Il-1b overex-
pression reflects the pro-inflammatory environment induced by
the hyperglycemia. In NHIR inflammation concurs with inhibited
vascularization and neuronal cell loss similar to ischemic DR and
ROP. If and how microglial cell activation, macrophage
recruitment and proinflammatory cytokine release influence
angiogenesis and neuronal apoptosis in NHIR is currently under
investigation.
We believe that NHIR provides a new model to study
inflammatory cascades during retinal development and will help
elucidate mechanisms of inflammation-induced damage to the
eyes of premature infants. Diabetic patients, and adult rodent
diabetic model, also show early retinal microglial cell activation
[31,33,34,35] and increased concentrations of cytokines and
chemokines [51,52,53]. NHIR might help decipher similarities
and differences in the role of inflammatory cells in retinal cell loss
in diabetic retinopathies and ROP.
Conclusion
Our model reproduces aspects of ROP (inhibited angiogenesis)
and common aspects of DR and ROP (neuronal cell death and
inflammation). In contrast to the OIR model, which displays little
inflammation, inflammation in NHIR is a prominent feature and
might help decipher the inflammatory aspect of hyperglycemia-
induced neuronal and vessel abnormalities in ROP. Compared to
other models of rodent diabetic retinopathy, our model has the
advantage of being short, having a pronounced phenotype, and
not requiring insulin treatment for animal survival.
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